home > ebr > autumn 2006 > nanodesign: triumph in tiny proportions


Dear guest!

article: Nanodesign: Triumph in Tiny Proportions
format: Adobe Acrobat PDF file
cost: £


News and Press Releases

BRIM Biotechnology Receives FDA Agreement on Phase 3 Clinical Trial Design for BRM421, BRIMís Lead Candidate for Dry Eye Disease, at End of Phase 2 Meeting

Taipei, Taiwan, 1st November 2022 / Sciad Newswire / BRIM Biotechnology, Inc. ("BRIM," TPEx 6885) is pleased to announce that it has received agreement from the US Food and Drug Administration (FDA) on the Phase 3 clinical trial design for its lead candidate for Dry Eye Disease (DED), BRM421, at the End of Phase 2 Meeting. BRIM will submit the Phase 3 study protocol to the FDA in Q4 2022.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement